Chronic Endometritis and Benefits of Antibiotics in Women With Recurrent Miscarriage

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age20-45
SponsorChinese University of Hong Kong

About this trial

The aim of the study is to estimate the incidence of CE, evaluate the endometrial microorganism of CE, and investigate the therapeutic benefits of antibiotics for women with unexplained recurrent miscarriage and CE.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Women with a history of 2 or more consecutive miscarriages before 24 weeks of gestation

Women aged 20-45 years old

Disqualifiers

Uncorrected uterine anomalies, such as the septate or bicornuate uterus, fibroids (submucous/intramural)

Untreated hydrosalpinx

Antiphospholipid syndrome

Known clinical autoimmune disease

Trial population

Subjects will be identified and recruited from the miscarriage clinic by clinicians and research assistants and research nurse.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Other intervention

    If the CE is high, antibiotics will be given to the patients as usual practice in hospitals.

Treatment groups

175 Participants
are divided into 1 treatment group
Group A: Observational study0 interventions

Trial outcomes

Primary outcomes

1

the incidence of chronic endometritis in local women with unexplained recurrent miscarriage

the incidence of chronic endometritis in local women with unexplained recurrent miscarriage

Time frame
31 January 2027

Secondary outcomes

1

Investigate the spectrum of endometrial microorganisms associated with chronic endometritis in this population

Investigate the spectrum of endometrial microorganisms associated with chronic endometritis in this population

Time frame
31 January 2027
2

Assess the clinical pregnancy outcomes between cured CE group and non-CE group

Assess the clinical pregnancy outcomes in both cured CE group and non-CE group

Time frame
31 January 2027

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.